Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Wins Japanese Approval For Cervarix As First Cervical Cancer Vaccine In Japan

This article was originally published in PharmAsia News

Executive Summary

TOKYO - GlaxoSmithKline K.K., the fully-owned Japanese subsidiary of GlaxoSmithKline, has won Japan's Ministry of Health, Labor and Welfare approval for cervical cancer vaccine Cervarix, the first cervical cancer vaccine to be marketed in Japan, the company announced Oct. 16
Advertisement

Related Content

GSK Names Former Sanofi Executive As President Of Japanese Affiliate
GSK Names Former Sanofi Executive As President Of Japanese Affiliate
GSK Files Japan's First Rotavirus Vaccine; Will Japan Become Next Battleground For Vaccine Makers?
GSK Files Japan's First Rotavirus Vaccine; Will Japan Become Next Battleground For Vaccine Makers?
Advertisement
UsernamePublicRestriction

Register

SC070134

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel